Alkem Launches Semaglutide in Single-Shot Pre-filled Syringes, Starting at INR350
Alkem Laboratories Limited has announced the launch of semaglutide in single-shot pre-filled syringes, marking the company as the first in India to introduce this format for the treatment of Type 2 diabetes mellitus and obesity. The new product format is available at a starting price of INR350.With this addition to its delivery portfolio, Alkem aims to lower entry barriers for patients requiring semaglutide treatment, while providing enhanced access and convenience through the ready-to-use single shot pre-filled syringe format.
The company confirmed that it has received the requisite approvals to manufacture and market semaglutide pre-filled syringes for managing Type 2 diabetes mellitus and obesity, specifically to be used as an adjunct to diet and exercise.
The launch follows Alkem's previous introduction of semaglutide in pre-filled disposable and reusable injection pens format in the Indian market in March 2026. Furthermore, the company has also received regulatory approval for semaglutide vials, which are expected to launch soon.
Dr. Vikas Gupta, Chief Executive Officer of Alkem, commented on the strategic significance of the launch. He stated, “Semaglutide has the potential to change how we manage metabolic disorders. With the launch of our pre-filled syringes, we are widening the choice available to doctors and patients, alongside the pen options we have already introduced. In India, where we are seeing a continuous rise in disease burden, offering multiple, practical drug delivery formats is an important step in helping more patients start and stay on the therapy.”
Alkem Laboratories Limited reiterated its commitment to advancing high-quality, affordable medicines across key therapeutic areas, supporting better patient care in India.
ALKEM Stock Price Movement
Alkem Laboratories Limited shares today slipped by 1.42% to settle at ₹5239 after a session marked by moderate selling pressure. The stock completed its trading day with a volume of 216,711 shares, registering a notable price decline.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.